[Congressional Record Volume 167, Number 93 (Thursday, May 27, 2021)]
[Senate]
[Page S3910]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 2104. Ms. WARREN submitted an amendment intended to be proposed to 
amendment SA 1502 proposed by Mr. Schumer to the bill S. 1260, to 
establish a new Directorate for Technology and Innovation in the 
National Science Foundation, to establish a regional technology hub 
program, to require a strategy and report on economic security, 
science, research, innovation, manufacturing, and job creation, to 
establish a critical supply chain resiliency program, and for other 
purposes; which was ordered to lie on the table; as follows:

        At the end of title III of division E, add the following:

     SEC. 5311. REPORT ON FOREIGN INVESTMENT FROM THE PEOPLE'S 
                   REPUBLIC OF CHINA IN PHARMACEUTICAL INDUSTRY.

       (a) In General.--Not later than 4 years after the date of 
     the enactment of this Act, the Federal Trade Commission and 
     the Commissioner of Food and Drugs, in consultation with the 
     Secretary of Commerce, shall submit to the appropriate 
     congressional committees, the Secretary of Health and Human 
     Services, and the Committee on Foreign Investment in the 
     United States a report on foreign investment from the 
     People's Republic of China in the pharmaceutical industry of 
     the United States.
       (b) Elements.--The report required by subsection (a) shall 
     include an assessment of--
       (1) the supply chain of the pharmaceutical industry of the 
     United States and the effect of concentration and reliance on 
     manufacturing in the People's Republic of China within that 
     industry;
       (2) the effect of foreign investment from the People's 
     Republic of China in the pharmaceutical industry of the 
     United States on domestic capacity to produce drugs and 
     active and inactive ingredients of drugs;
       (3) the effect of foreign investment from the People's 
     Republic of China in technologies or other products for 
     sequencing or storage of DNA, including genome and exome 
     analysis, in the United States, including the effect of such 
     investment on the capacity to sequence or store DNA in the 
     United States; and
       (4) the value and feasibility of providing additional 
     reports every 4 years to Congress on the matters described in 
     paragraphs (1), (2), and (3), for the purposes of 
     strengthening the domestic capacity of the United States to 
     produce drugs and active and inactive ingredients of drugs.
       (c) Preventing Duplication.--The Federal Trade Commission, 
     the Commissioner of Food and Drugs, and the Secretary of 
     Commerce shall consult with other Federal agencies to prevent 
     the duplication of reporting on the domestic drug supply 
     chain in the development of the report required by subsection 
     (a).
       (d) Authority.--The Federal Trade Commission shall have 
     authority under section 6 of the Federal Trade Commission Act 
     (15 U.S.C. 46) to conduct the studies required to prepare the 
     report required by subsection (a).
       (e) Publication.--The Federal Trade Commission shall 
     publish an unclassified summary of the report required by 
     subsection (a) on a publicly available internet website of 
     the Commission.
       (f) Appropriate Congressional Committees Defined.--In this 
     section, the term ``appropriate congressional committees'' 
     means--
       (1) the Committee on Banking, Housing, and Urban Affairs, 
     the Committee on Health, Education, Labor, and Pensions, the 
     Committee on Armed Services, the Committee on Foreign 
     Relations, the Committee on Commerce, Science, and 
     Transportation, and the Committee on Appropriations of the 
     Senate; and
       (2) the Committee on Financial Services, the Committee on 
     Energy and Commerce, the Committee on Armed Services, the 
     Committee on Foreign Affairs, and the Committee on 
     Appropriations of the House of Representatives.
                                 ______